vimarsana.com

Latest Breaking News On - Dr reddys labs - Page 2 : vimarsana.com

Revlimid overdose boosts Dr Reddy s Q3 earnings, but turns brokerages cautious

While Dr Reddy s recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug Revlimid while the base US and India business delivered a subpar performance.

MC Pro Quick Take: Sun Pharma s US sales outpace Dr Reddy s, Cipla in Q3

Sun Pharma’s specialty drugs business continue to grow at a brisk pace, helped by ramp-up of key products

Dr Reddy s Q3 results: Net profit up 11% to Rs 1,378 crore, marginally misses estimates

Trade Spotlight | Your blueprint for Aditya Birla Fashion, Dr Reddy s and Borosil Renewables

Aditya Birla Fashion & Retail has seen a nice breakout of consolidation and maintained upward sloping support trendline. The stock formed strong bullish candlestick pattern on the daily charts with healthy volumes.

Moneycontrol Pro Panorama | Cipla s results reassure pharma investors

In today s edition of Moneycontrol Pro Panorama: Ayodhya impact on general elections in the South, new budget schemes can unlock tourism potential, Middle-East is now a powder keg waiting to explode, budget allotment for science to make a big bang, and more

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.